In an extraordinary year for the Korean pharmaceutical and biotech industry, the sector has achieved a new milestone with 14 companies successfully finalizing 17 technology export deals, showcasing its growing global presence and innovative capabilities.The 14 companies include, Daewoong Pharmaceuti
Eagle Vet, an animal pharmaceutical company, said Friday that it signed a contract manufacturing organization (CMO) agreement with Orion, a Finnish pharmaceutical company, to supply Oriverm (ivermectin), an animal anthelmintic injection.It took six years for Eagle Vet to select the product to be sup
AstraZeneca Korea has received marketing authorization for Tezspire (tezepelumab), a treatment for severe asthma in Korea.The Ministry of Food and Drug Safety (MFDS) approved Tezpire on Thursday.Tezspire is an anti-TSLP monoclonal antibody that binds to thymic stromal lymphopoietin (TSLP), which cau
Yuhan Corp.’s lung cancer treatment Leclaza (lazertinib) has made the first step into the global pharmaceutical market as a Korean-made anticancer drug. On Thursday, Janssen Pharmaceuticals, a pharmaceutical company wholly-owned by Johnson & Johnson, said that it submitted a marketing authorization
From Jan. 1, AstraZeneca's Tagrisso (osimertinib) and Yuhan Corp.'s Leclaza (lazertinib) will get health insurance coveraget for the first-line treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC).Koselugo (selumetinib), developed by AstraZeneca and MSD, will be also cover
Keytruda (pembrolizumab), MSD's anti-PD-1cancer immunotherapy, has received approval for two additional indications in Korea.MSD Korea said Keytruda received the permit from the Ministry of Food and Drug Safety (MFDS) as a first-line treatment in adult patients with HER2-positive advanced gastric ca
The Korean ankylosing spondylitis treatment market is at a significant turning point thanks to the expansion of health insurance benefits for related drugs, an expert said. Ankylosing spondylitis, if left untreated, can lead to a hunched back and stiff neck. Typically, the disease begins with altern
Boryung and HK inno.N have entered into an agreement for the joint marketing of their flagship drugs, Kanarb (pimasartan) and K-CAB (tegoprazan), starting January next year. Under this collaboration, Boryung will jointly market HK inno.N's K-CAB Tab and K-CAB ODT, while HK inno.N will jointly market
LG Chem, which is developing a gout treatment, has taken a step closer to global clinical trials in Europe.LG Chem said in a public filing on Tuesday that the company has received conditional approval from the Italian regulator Agenzia Italiana del Farmaco (AIFA) for a phase 3 clinical trial (EURELI
Dong-A ST said Wednesday that it has acquired AbTis, a company specializing in antibody drug conjugate (ADC).Dong-A ST did not disclose an acquisition cost for the deal.AbTis has developed AbClick, an ADC technology that can site-selectively conjugate drugs without antibody modification.ADC is an an
Bristol Myer Squibb (BMS)’s Camzyos has emerged as a groundbreaking treatment for obstructive hypertrophic cardiomyopathy (oHCM), a rare disease in which the muscle in the pumping chamber of the heart becomes thickened, an expert said in an interview with Korea Biomedical Review. Until now, the only
Daewoong Pharmaceutical and Medytox are set to compete in the submental fat improvement injectable market, following botulinum toxin (BTX).Medytox said it applied for a new prdoduct license from the Ministry of Food and Drug Safety for NEWV (MT921 in development name), a lipolysis injection with the
PharmaEssentia's Besremi (ropeginterferon alfa-2b), a treatment for polycythemia vera (PV), showcased exceptional therapeutic efficacy, achieving complete hematologic and molecular biologic responses in Korean patients who did not respond to hydroxyurea therapy, a study showed. Professor Lee Sung-eu
HLB, a Kosdaq-listed anticancer drug developer, said that the combination of the targeted therapy rivoceranib and immunotherapy camrelizumab has proved effective not only in hepatocellular carcinoma (HCC) but also in lung cancer in a phase 2 clinical trial.HLB reported that Jiangsu Hengrui Pharmaceu
Gemvax & Kael, a Kosdaq-listed peptide drug specialist, said on Tuesday that it has submitted a phase 2 investigational new drug (IND) application to the U.S. FDA for GV1001, targeting the treatment of progressive supranuclear palsy (PSP).PSP is an atypical Parkinson's syndrome characterized by rapi
Patients with severe hemophilia A often have to give up even light physical activities due to joint pain, let alone exercise.However, a recent study has shown that these patients drastically improved their quality of life by reducing the frequency of bleeding and could engage in physical activities
Celltrion said Monday that it has received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for a phase 1 Investigational New Drug (IND) application for CT-P55, a Cosentyx (secukinumab) biosimilar for the treatment of psoriasis.Developed by Novartis, Cosentyx is an interl
C&C Research Labs, a subsidiary of JW Pharmaceutical, and XtalPi, a U.S.-based artificial intelligence drug development company, said they will cooperate in developing small molecule therapeutics, focusing on targeting the STAT6 protein, a key player in inflammatory immune responses.XtalPi, founded
For decades, platinum-based chemotherapy has been the gold standard for treating locally advanced or metastatic urothelial cancer. However, the advent of antibody-drug conjugates (ADCs) has changed the treatment of urothelial cancer.In addition to providing a new option as a last resort to urothelia
The Ministry of Food and Drug Safety (MFDS) has imposed administrative penalties for pharmaceutical companies that violated GMP (good manufacturing practice) rules.According to the ministry, CMIC CMO Korea received a 15-day administrative penalty on Dec. 5 to suspend the manufacturing of its ointmen